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Ginseng is a widely used herbal product in China, other Asian countries, and the United States. 1 For thousands of years, people in China have used ginseng as a tonic and, in emergency medicine, to rescue dying patients. Ginseng means "essence of man" in Chinese. The Chinese ginseng that grows in Manchuria is Panax ginseng. This ginseng, commonly termed Asian ginseng, is a preparation of ginseng root. In the American market, Asian ginseng is sold as liquid extract or capsules. Dried ginseng root also is available in the American market. Ginseng is promoted as a tonic capable of invigorating the user physically, mentally, and sexually. It also is used to deal with stress because of its calming effect.
Although in the United States herbal medicines are sold as food supplements and not regulated by the US Food and Drug Administration, in Germany the German Commission E publishes monographs on safety of herbal medicines. The monographs are prepared by an interdisciplinary committee using historic information; chemical, pharmacologic, clinical, and toxicologic studies, including case reports; epidemiologic data; and unpublished manufacturer's data. If an herbal product has an approved monograph, it can be marketed. The German Commission E approves Asian ginseng as a nonprescription tonic for invigoration and fortification during fatigue and also for reversal of declining work capacity and concentration.
Although both Asian and Siberian ginsengs are sold under the broad category of ginseng, Siberian ginseng is different from Asian ginseng because it is prepared from a different plant. Siberian ginseng is prepared from the root of Eleutherococcus senticosus and also is imported from China. Hikino et al 2 isolated 7 glycans from a crude extract of Siberian ginseng. Recently, Li et al 3 isolated a new ligand glycoside named eleutheroside E(2) from Siberian ginseng.
The structures of eleutherosides are different from the saponin structures found in Asian ginseng (P ginseng). The saponins found in Asian ginseng also are known as ginsenosides. Many ginsenosides have been isolated and characterized from Asian ginseng. 4 Eleutherosides and ginsenosides have some structural similarity with digoxin. Owing to widespread use of ginseng by the general population, it is possible that a person receiving digoxin also is taking ginseng without the knowledge of the primary care physician. Eisenberg et al 5 reported that 75% of patients do not inform their physicians about their use of alternative medicines. Digoxin is a cardiac glycoside with a very narrow therapeutic range (0.8-1.9 ng/mL [1.0-2.4 nmol/L]), and routine monitoring of the digoxin level is essential to avoid toxic effects of digoxin.
The potential interference of Asian ginseng in serum digoxin measurements has not been studied properly. However, there is a case report of the interference of Siberian ginseng in serum digoxin measurements. In 1 patient, a serum digoxin level of 5.2 ng/mL (6.7 nmol/L) was reported, but the patient had no symptoms of toxic effects of digoxin. When use of the Siberian ginseng was discontinued, his digoxin level returned to the therapeutic range. 6 Herbal preparations do not follow the rigorous standards of product standardization, quality control, and purity required for pharmaceutical preparations. Therefore, there may be a wide variation in the concentrations of active ingredients in the same herbal product prepared by different manufacturers. Recently, Datta and Dasgupta 7 reported wide variation in digoxin-like immunoreactivity and the magnitude of interference in serum digoxin measurements by different brands of the Chinese medicines Chan Su and Dan Shen. One Dan Shen product showed no interference in serum digoxin measurements, while the other 2 products showed interference. 7 In the present study, we examined 3 brands of Asian and 3 different brands of Siberian ginseng for their digoxin-like immunoreactivity in vitro and in vivo (mouse model) and for their potential interference in serum digoxin measurements using 5 digoxin immunoassays.
Materials and Methods
Two different liquid extracts of Asian ginseng root were purchased from Chinatown in Houston, TX. The first product was manufactured by Wai Shing Trading Company, Central, Hong Kong (A1), and the second product was the Song Shiu Pan brand (A2) of P ginseng. The capsule form of Asian ginseng (A3) was marketed by Whole Foods Market (Austin, TX). The first brand of Siberian ginseng capsule (S1) was manufactured by Rexall Sundown (Boca Raton, FL), and the second brand (S2) was produced by Root to Health (Wausau, WI). The liquid Siberian ginseng extract (S3) was manufactured in China and distributed by Z.T. Universal (Glen Head, NY).
The fluorescence polarization immunoassay (FPIA) for digoxin was obtained from Abbott Laboratories (Abbott Park, IL). Digoxin concentrations were measured using a TDx/FLX analyzer, also from Abbott Laboratories. The microparticle enzyme immunoassay (MEIA) kits for digoxin were obtained from Abbott Laboratories, and assays were run on an AxSYM analyzer (Abbott Laboratories). The EMIT (enzyme multiplied immunoassay) 2000 digoxin assay kits were obtained from Dade Behring (Deerpark, IL), and the assay was run on the ADVIA 1650 analyzer (Bayer Diagnostics, Tarrytown, NY). The Randox digoxin assay (Randox Laboratories, Antrim, Northern Ireland) also was run on the ADVIA 1650 analyzer. The chemiluminescent assay (CLIA) for digoxin was performed using an ACS:180 Plus analyzer (Bayer Diagnostics). The ultrafiltration devices (Microcon Micropartition System) were purchased from Millipore (Danvers, MA). This device contains an anisotropic hydrophilic membrane (YMT) with narrow pore size distribution and a molecular weight cutoff of 30,000 d. Typically, this device retains 99.9% of the serum protein and less than 5% L-thyroxine.
The MEIA, EMIT, Randox, and CLIA do not require sample pretreatment, but the FPIA requires a sample pretreatment. For this purpose, 200 µL of serum was mixed with 200 µL of sulfosalicylic acid in 50% methanol. After protein precipitation, the specimen was centrifuged at a high speed, and the clear supernatant was analyzed for digoxin concentration. The assay is linear up to a serum digoxin concentration of 5.0 ng/mL (6.4 nmol/L), and the assay sensitivity is 0.2 ng/mL (0.3 nmol/L). The MEIA is linear up to a serum digoxin concentration of 4.0 ng/mL (5.1 nmol/L), and the assay sensitivity is 0.3 ng/mL (0.4 nmol/L). The EMIT 2000 and the CLIA were run according to the kit manufacturers' protocols. The CLIA is linear to a serum digoxin concentration of 5.0 ng/mL (6.4 nmol/L), and the assay sensitivity is 0.15 ng/mL (0.2 nmol/L). The dynamic range of the EMIT is 0.2 to 5.0 ng/mL (0.3-6.4 nmol/L), and the detection limit is 0.20 ng/mL (0.3 nmol/L). The Randox digoxin assay also was linear to a digoxin concentration of 5.0 ng/mL (6.4 nmol/L), and the assay sensitivity was 0.20 ng/mL (0.3 nmol/L). The respective manufacturers provided the linearity and detection limit data for individual digoxin assays.
Stock solution of Asian ginseng (25 mg/mL) was prepared in ethyl acetate. The liquid Asian ginseng preparations were in aqueous medium and were used directly for supplementation in serum. Ethyl acetate was used for preparing the standard solution of Siberian ginseng (capsule form) at a concentration of 25 mg of solid powdered Siberian ginseng per milliliter of ethyl acetate. Similarly, the liquid Siberian ginseng was used for supplementation purposes in serum pools.
We supplemented aliquots of drug-and digoxin-like immunoreactive substance (DLIS)-free serum with microliter quantities of Asian or Siberian ginseng and measured apparent digoxin concentrations by using the FPIA, MEIA, EMIT, Randox, and CLIA. To ensure that the serum pools did not contain DLISs, we measured the apparent digoxin level using the FPIA and ensured that the apparent digoxin concentration was "none detected." The FPIA shows high cross-reactivity with DLISs. To avoid any matrix effect due to ethyl acetate, ginseng extract was added to a tube first, and we evaporated ethyl acetate under nitrogen. Then the dried extract was reconstituted with serum. The liquid Asian and Siberian ginseng products were aqueous-based and were used directly. Aqueous extracts of Asian or Siberian ginseng roots should not alter serum matrix substantially.
To investigate whether digoxin-like immunoreactivity also occurs in vivo, mice were fed liquid extract (100 µL) of Asian or Siberian ginseng. Mice also were fed solid powdered Asian or Siberian ginseng (50 mg/kg). Blood samples were obtained 1 day before the feeding experiment to demonstrate the absence of endogenous digoxin-like immunoreactivity in mice. Blood samples also were obtained 1 hour after feeding with Asian or Siberian ginseng, and the apparent digoxin concentration was measured by using the FPIA for digoxin.
In separate experiments, changes in apparent digoxin concentrations due to the Chinese medicines were examined by supplementing serum pools (prepared from samples from patients receiving digoxin) with Asian or Siberian ginseng. These specimens are submitted routinely to our clinical laboratory. Leftover specimens were used after tests ordered by physicians had been performed and results reported. We prepared several serum pools using multiple specimens from different patients in each pool. One digoxin pool prepared from volume-expanded patients contained a substantial amount of endogenous DLISs. Aliquots of these pools were supplemented with various amounts of Asian or Siberian ginseng, and digoxin concentrations were measured by using the FPIA, MEIA, EMIT, Randox, and CLIA. The amounts of Asian or Siberian ginseng added to digoxin pools were based on expected concentrations of these ginsengs in serum if half or more of the components are absorbed from the stomach.
In another experiment, we studied the possibility of eliminating the interference of Asian ginseng in the FPIA and MEIA for digoxin by measuring digoxin concentrations in the protein-free ultrafiltrate. Protein-free ultrafiltrate was prepared by centrifuging specimens in the Centrifree Micropartition System (Amicon, Danvers, MA) for 30 minutes at 2500g.
Statistical analyses were performed using the 2-tailed independent t test. We considered a difference significant only at a confidence interval of 95% or higher (P < .05).
Results
Significant digoxin-like immunoreactivity was observed in 1 liquid Asian ginseng preparation (A2 µL of extract was added per milliliter of drug-and DLIS-free serum. Brands A3, S1, and S2 were capsules: standard solution was prepared by adding 25 mg of dry powder to 1 mL of ethyl acetate; then 25 µL of extract was added per milliliter of drug-and DLIS-free serum. For additional information about the brands of ginseng used and for proprietary information, see the "Materials and Methods" section. When no digoxin was detected, the value was lower than the sensitivity of the assay.
liquid ginseng preparation (Asian or Siberian) per milliliter of drug-and DLIS-free serum.
To investigate whether digoxin-like immunoreactivity due to Asian and Siberian ginseng also can occur in vivo, we fed Asian or Siberian ginseng to mice. Blood samples obtained the day before feeding with ginseng demonstrated no digoxin-like immunoreactivity. However, blood samples obtained 1 hour after feeding with Asian or Siberian ginseng demonstrated significant digoxin-like immunoreactivity by FPIA (range, Asian ginseng, 0.48-0.68 ng/mL [0.6-0.9 nmol/L]; Siberian ginseng, 0.20-0.47 ng/mL [0.3-0.6 nmol/L]), indicating that such effects also occur in vivo ❚Table 2❚. We observed an apparent digoxin concentration of 0.21 ng/mL (1.5 nmol/L) in 1 mouse fed with Siberian ginseng (S1). In some cases, a mouse may regurgitate a part of the liquid fed by gavage, and this may be why the apparent digoxin concentration was relatively low in mouse 5 compared with the concentration for mouse 6, which showed an apparent digoxin concentration of 0.47 ng/mL (0.6 nmol/L; both fed with S1). We were unable to repeat the digoxin measurement in an individual mouse because of the small blood volume. However, observing apparent digoxin levels in all mice fed with Asian or Siberian ginseng indicates the validity of our observations.
Cross-reactivity of an interfering substance in an immunoassay should be studied in the presence of the primary analyte. 8 Therefore, we supplemented serum pools (prepared from samples from patients receiving digoxin) with Asian or Siberian ginseng, measured apparent digoxin concentrations with all 5 digoxin immunoassays, and compared the apparent digoxin concentrations with control values. In these studies, only the ginseng preparations that showed digoxin-like immunoreactivity (A2, S1, S3) in our first experiment were used. We observed falsely increased serum digoxin concentrations when digoxin pools were supplemented with the liquid Asian ginseng (A2), and apparent digoxin concentrations were measured using the FPIA for digoxin. In contrast, apparent digoxin concentrations were falsely decreased when the MEIA was used. No statistically significant changes in serum digoxin concentrations were observed in the presence of Asian ginseng when the EMIT, Randox, and CLIA were used ❚Table 3❚. The slightly lower digoxin values observed with the Randox assay may be related to a slight method-to-method variation in different assays. However, such small bias is not clinically significant.
Asian and Siberian ginsengs showed synergistic effects with endogenous DLISs in further falsely increasing or decreasing apparent digoxin concentrations, depending on the immunoassay. Digoxin pool 3 was prepared from samples obtained from patients with volume expansion and receiving digoxin. The concentration of digoxin was 1.68 ng/mL (2.2 nmol/L) as measured by the FPIA, 1.10 ng/mL (1.4 nmol/L) as measured by the MEIA, and 1.28 ng/mL (1.6 nmol/L) as measured by the CLIA. The CLIA is free from interference from endogenous DLISs. 9 The falsely increased value as demonstrated by the FPIA and falsely decreased digoxin level as shown by the MEIA indicates that digoxin pool 3 also had a substantial level of endogenous DLISs. 10 Asian ginseng showed a synergistic effect with DLIS in further increasing the apparent digoxin level as measured by the FPIA. The value was falsely elevated to 2.05 ng/mL (2.6 nmol/L) when 10 µL of Asian ginseng extract (A2) was added to 1 mL of digoxin pool 3. The value was falsely decreased to 0.85 ng/mL (1.1 nmol/L) when the MEIA was used for serum digoxin measurement. However, no statistically significant change in the serum digoxin concentration was observed in the presence of Asian and Siberian ginsengs in digoxin pool 3, which also had elevated levels of DLISs (Table 3) .
DLISs of Asian ginseng are less than 50% bound to serum protein. For example, when a drug and DLIS-free serum mixture was supplemented with Asian ginseng, the total apparent digoxin concentration was 0.84 ng/mL (1.1 nmol/L), and the free apparent digoxin concentration was 0.45 ng/mL (0.6 nmol/L). Therefore, elimination of this interference in serum digoxin measurement by FPIA and MEIA cannot be achieved by monitoring the free digoxin concentration. For example, in a digoxin pool containing 1.06 ng/mL (1.4 nmol/L) of free digoxin (total, 1.51 ng/mL [1.9 nmol/L] by FPIA), the free digoxin concentration was increased to 1.22 ng/mL (1.6 nmol/L) in the presence of 10 µL of Asian ginseng (A2). The increase in the free digoxin concentration was statistically significant (P < .05). Similarly, when we used the MEIA for the serum digoxin measurement, we observed significantly lower free digoxin in the presence of Asian ginseng, indicating that interfering substances also were present in the protein-free ultrafiltrate
The interference of Siberian ginseng in the serum digoxin measurement using the FPIA and MEIA cannot be eliminated by the ultrafiltration technique because DLISs of Siberian ginseng are not strongly protein bound like the immunoreactive factors of Asian ginseng. For example, the total digoxin levels (as measured by the FPIA) increased from a control value of 0.76 ng/mL (1.0 nmol/L) to 0.94 ng/mL (1.2 nmol/L) in the presence of 10 µL of Siberian ginseng extract per milliliter of serum digoxin pool. The value was increased further to 1.03 ng/mL (1.3 nmol/L) in the presence of 20 µL of Siberian ginseng extract per milliliter of the same digoxin pool. The free digoxin value in the control specimen was 0.51 ng/mL (0.7 nmol/L). The free digoxin values were increased to 0.60 ng/mL (0.8 nmol/L) and, finally, to 0.65 ng/mL (0.8 nmol/L) in the presence of 2 different doses of Siberian ginseng. Significant increases in free digoxin values indicate the presence of DLISs of Siberian ginseng in the protein-free ultrafiltrate.
Discussion
Significant digoxin-like immunoreactivity was observed using the FPIA with 1 liquid Asian ginseng preparation. Another liquid Asian ginseng preparation and 1 capsule form did not show digoxin-like immunoreactivity. This finding indicates that DLISs were present in different amounts in various preparations of Asian ginseng. We also observed no digoxin-like immunoreactivity in 1 capsule form of Siberian ginseng. This may cause confusion in interpreting results for therapeutic monitoring of digoxin because 1 brand of ginseng may interfere with serum digoxin measurement, whereas another ginseng preparation manufactured by a extract was added per milliliter of drug-and DLIS-free serum. Brand S1 was a capsule: standard solution was prepared by adding 25 mg of dry powder to 1 mL of ethyl acetate; then 25 µL of extract was added per milliliter of drug-and DLIS-free serum. For additional information about the brands of ginseng used and for proprietary information, see the "Materials and Methods" section. When no digoxin was detected, the value was lower than the sensitivity of the assay. † Pool 3 had high endogenous DLIS as evidenced by discrepancies in the digoxin values measured by FPIA (falsely increased) and by MEIA (falsely decreased). ‡ Significantly greater than the control value (P < .05; 2-tailed t test). § Significantly less than the control value (P < .05; 2-tailed t test). different manufacturer may not have an effect on serum digoxin measurement. Relative to Asian ginseng, Siberian ginseng showed only modest interference in serum digoxin measurement by the immunoassays. McRae 6 reported a case in which Siberian ginseng was associated with an elevated digoxin level in a 74-year-old man. In this patient, the serum digoxin level had been maintained between 0.9 and 2.2 ng/mL (1.2-2.8 nmol/L) for a period of 10 years. After ingestion of Siberian ginseng, his serum digoxin level increased to 5.2 ng/mL (6.7 nmol/L), although the patient did not show any symptoms of toxic effects of digoxin. The patient stopped taking ginseng, and his digoxin level returned to normal. 6 McRae observed almost a 300% increase in serum digoxin concentration due to the presence of Siberian ginseng, a very high interference in the digoxin immunoassay. In our in vivo experiment, we observed only modest digoxin-like immunoreactivity when mice were fed a dose comparable to the recommended dose for humans based on body weight. Our in vitro experiments showed roughly 15% to 20% increases in serum digoxin values in the presence of Siberian ginseng, a modest interference. Misidentification of Chinese herbs is a common problem. Several reports indicated toxicity of a Chinese herb, which later was identified as being due to a different species. The substantial interference of Siberian ginseng in 1 patient as reported by McRae 6 seems unusual in comparison with our study of the potential interference of Siberian ginseng in serum digoxin measurements by immunoassays. One possibility is that the Siberian ginseng the patient was taking was a different Chinese medicine that was wrongly labeled "Siberian Ginseng." The extent of the high interference in digoxin measurement in this patient is more consistent with the use of another Chinese medicine, Chan Su; Chan Su contains bufalin and related compounds, which show high cross-reactivity with some digoxin immunoassays. [11] [12] [13] [14] Asian and Siberian ginsengs act synergistically with DLISs in further falsely increasing (FPIA) or decreasing (MEIA) serum digoxin concentrations. For example, in digoxin pool 3 (high DLIS level), the digoxin concentration in the presence of Asian ginseng as measured by the FPIA was 2.05 ng/mL (2.6 nmol/L), whereas the digoxin concentration as measured by the MEIA was 0.85 ng/mL (1.1 nmol/L). This could be a confusing situation if a patient is transferred from a hospital in which the FPIA is used to another hospital in which the MEIA is used for digoxin measurement.
Interference of Asian ginseng in the serum digoxin measurement by the FPIA and MEIA cannot be eliminated by monitoring the free digoxin concentration because the DLISs of Asian ginseng are poorly bound to serum protein.
